S-Equol in Alzheimer's Disease 2 Trial

Summary

By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity. Researchers also hope to determine the safety and tolerability of a therapeutic dose of S-equol and whether or not it influences cognition.

Timeline

Start

2017-05-05

Primary completion

2021-03-01

Completion

2021-03-01

Drugs

Indications